Toroso Investments LLC boosted its holdings in Zoetis Inc. (NYSE:ZTS – Get Rating) by 2.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,250 shares of the company’s stock after purchasing an additional 171 shares during the quarter. Toroso Investments LLC’s holdings in Zoetis were worth $927,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Trexquant Investment LP increased its stake in Zoetis by 264.9% in the 3rd quarter. Trexquant Investment LP now owns 32,166 shares of the company’s stock valued at $4,770,000 after buying an additional 23,352 shares during the period. Stock Yards Bank & Trust Co. acquired a new position in Zoetis in the 2nd quarter valued at $994,000. Pinnacle Associates Ltd. increased its stake in Zoetis by 11.1% in the 3rd quarter. Pinnacle Associates Ltd. now owns 7,050 shares of the company’s stock valued at $1,045,000 after buying an additional 702 shares during the period. U.S. Capital Wealth Advisors LLC increased its stake in Zoetis by 77.8% in the 3rd quarter. U.S. Capital Wealth Advisors LLC now owns 9,951 shares of the company’s stock valued at $1,476,000 after buying an additional 4,354 shares during the period. Finally, Personal Capital Advisors Corp increased its stake in Zoetis by 5.5% in the 3rd quarter. Personal Capital Advisors Corp now owns 1,950 shares of the company’s stock valued at $289,000 after buying an additional 102 shares during the period. Hedge funds and other institutional investors own 90.23% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities analysts have issued reports on ZTS shares. Barclays boosted their price objective on shares of Zoetis from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Tuesday, February 21st. StockNews.com began coverage on shares of Zoetis in a report on Thursday. They set a “buy” rating on the stock. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $223.83.
Zoetis Trading Down 1.1 %
Zoetis (NYSE:ZTS – Get Rating) last released its quarterly earnings results on Tuesday, February 14th. The company reported $1.15 EPS for the quarter, meeting the consensus estimate of $1.15. The business had revenue of $2.04 billion for the quarter, compared to analyst estimates of $2.01 billion. Zoetis had a net margin of 26.16% and a return on equity of 50.20%. The company’s quarterly revenue was up 3.7% on a year-over-year basis. During the same period in the prior year, the business earned $1.00 earnings per share. On average, research analysts predict that Zoetis Inc. will post 5.39 earnings per share for the current fiscal year.
Zoetis Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 1st. Stockholders of record on Friday, April 21st will be given a $0.375 dividend. The ex-dividend date is Thursday, April 20th. This represents a $1.50 annualized dividend and a dividend yield of 0.91%. Zoetis’s dividend payout ratio is presently 33.33%.
Zoetis Company Profile
Zoetis, Inc engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The United States segment is involved in U.S.
Recommended Stories
- Get a free copy of the StockNews.com research report on Zoetis (ZTS)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Get Rating).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.